Emphysema Clinical Trial
Official title:
Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Chronic Obstructive Pulmonary Disease Phenotype
AIM: To identify those mechanisms involved in the systemic and muscular response to exercise
treatment, in two different Obstructive Chronic Pulmonary Disease (COPD) phenotypes
(emphysema and non-emphysema). The investigators will evaluate the effect of exercise
training, on exercise outcomes, peripheral muscle strength measures, dyspnea and quality of
life indices, and markers of systemic inflammation and muscle repair.
SUBJECTS: The investigators will study 30 COPD patients in GOLD II-IV stages, with
symptomatic disease. Patients will be differentiated into 2 different phenotypes:
predominant-emphysema and non-predominant emphysema (15 subjects for each group), according
to high resolution computed tomography (HRCT) scanning images, and after the specific
analysis with the MeVisPulmo software. After patients are typified, they will be included in
the 12- wk training programme. MEASURES(pre&post-training):Basic blood analysis, EKG,
spirometry, blood gases, pletysmography, gas diffusion, maximal inspiratory and expiratory
pressure (MIP,MEP), bioimpedanciometry, 1RM test and isometric strength determination, 6-min
walking test (6MWT), maximal and submaximal cycle-ergometry, and dyspnea using the Mahler's
Basal and Transitional Dyspnoea Indexes (BDI/TDI) and quality of life (Chronic Respiratory
Disease Questionnaire [(CRDQ]) evaluation. Besides, the investigators will measure blood PCR
and cytokines levels (IL6, IL8, IL10, IL12, TNF-α, IGF-1, and MIC-A & MIC-B). Muscle
biopsies will be made (quadriceps) for detection of TNF-α, TNFR-I, TNFR-II, IGF-1Ea and MGF,
IGF-1R, genes bound to biogenesis, markers of cell lesion-stress and myosin heavy chains
(MyHC) type I and II, N-CAM/CD56 and Met & Desmin
STUDY POPULATION: Patients diagnosed COPD using the criteria established by the ATS
(American Thoracic Society) and the SEPAR (Spanish Society of Pneumology and Thoracic
Surgery) obstruction presenting moderate to severe airway obstruction (FEV1 <60%) and a
clinical impact of their disease. Patients should be stable and appropriate therapy, and
must not have suffered exacerbations of the disease over a period of three months before the
study, and without treatment with oral corticosteroids for at least the same period.
SAMPLE SIZE: 30 patients diagnosed at the Department of Pulmonology, Hospital Virgen del
Rocío de Sevilla, informed consent.
Sample size calculation: Analyzing the effect size at the expense of an improvement in the
work achieved over 15 W in the stress test, and considering a standard deviation of this
parameter + / - 10W, allowing to detect differences in metabolic variables muscle, taking
some risks alpha <0.05 and beta < 0, 2 and calculating a percentage of losses of 15%, the
investigators estimate a sample size of 15 patients for each group (PC-size).
EXIT CRITERIA OF THE STUDY:
- patient's clinical decompensation
- Loss of 3 or 5 consecutive sessions of the training program discontinued.
- On the initiative of the patient
CHARACTERISTICS OF GROUPS AND STUDY DESIGN:
This is a prospective case-control, with a double oriented ex vivo and in vitro.
Patients differ in COPD "dominance emphysema" (15 patients) or COPD without "predominantly
emphysema" (15 patients) achieved according to objective criteria for quantitative methods
of a Computed Tomography High Resolution.
The study will follow the recommendations of the Helsinki Declaration on human
experimentation and security levels of data protection required by Law 15/1999 of December
13. The study was approved by the ethics committee of our institution and will obtain the
informed consent of the individuals recruited.
TRAINING PROGRAM OF THE YEAR:
All patients underwent a training program to be held for 12 weeks in sessions of 60 minutes:
1. .- 20 minutes of bicycle ergometer with an initial load level of about 70% of baseline
peak oxygen consumption, increasing the load every two weeks as tolerated.
2. - Weightlifting in 2 sets of 6 reps of 5 simple exercises. These are held at a station
multigimnastyc (CLASSIC Fitness Center, KETTLER) and comprise: or simple arm flexion
(pull cable to the chest "Chest pulls"): effects on the latissimus dorsa, deltoids and
biceps. Sitting facing the tower drive, approaching the bar to the chest and then
extending your arms after you return to the starting position.
or simple extension of the arms ("Shoulder press"): Effects on the deltoids and triceps.
Sitting upright on the bench and held the weight to shoulder height, there will be extending
your arms above your head, slowly returning after bending arms to the starting position.
or arm flexion and extension against resistance (Butterfly "Butterfly"): Effects on the
pectoral and deltoid muscles. Sitting upright on the bench with your forearms and elbows on
a lever, takes it to the midline, giving way slowly to the starting position.
or leg stretching ("Leg extension"): Effects on the quadriceps. Sitting on the bench leg
extension is performed against resistance.
or squats ("Leg curls"): Effects on the biceps femorals and calves. Lying prone on the bench
legs are bent against the weight.
The resistance will be increased gradually from 70% of the maximum weight you can lift the
patient in a single maneuver (Test 1RM). Every two weeks the maximum weight is re-evaluated
to adjust the training load in each patient.
VARIABLES, SAMPLING AND MEASUREMENT:
All patients underwent baseline and after the training program the following tests.
- Analytical elemental, 12-lead electrocardiogram
- Spirometry and bronchodilator test simple: be held in a Datospir 92 at baseline and
after administration of 200 micrograms of salbutamol
- Blood gases
- static lung volumes (FRC, RV, TLC) by plethysmography.
- Study of diffusion (DLCO) by single breath technique (equipment Masterlab).
- maximum muscle pressures both inspiratory and expiratory, using a specific gauge (Micro
Medical, Rochester, USA) connected to a pressure transducer and a digital recording
system.
- chest CT (only at baseline): Phillips Tomoscan with Easy Vision workstation version 4.2
that allows densitometric analysis of lung parenchyma. Quantitative analysis of the
degree of emphysema was performed using the software 3D MeVisPULMO (MeVis Research,
Research Partner, University of Bremen, Germany). This is a prototype of software that
allows functional diagnosis based on CT images and in relation to the anatomical
compartments of the lung. Includes automated segmentation of the airway, lungs, lung
lobes and segments sublobar approach. This feature makes it especially useful to
enhance the diagnostic process in severe lung disease. The analysis software provides a
regional assessment MeVisPULMO allows proper parameters measured by CT lung, such as:
the total volume, mean density, pixel index or index of bullae (7.22).
- Assessment of muscle strength:
1. Test one repetition maximum (1 RM test) measures the maximum amount of weight (in
kg) that can be raised in a single maneuver using a multigimnastyc station
(Classic Fitness Centre, Kettler, Postfach, USA). It can for each of the five
exercise of upper and lower limbs that are developed (chest pull, butterfly,
shoulder press, leg extension and leg curls).
maximal isometric quadriceps b.strength dominant. There will be a quad chair specially
prepared for this procedure (HUR Labs, Sanro) and using a dynamometer cable (Performance
recorder). There will be at least 3 maneuvers of maximal isometric force of 5 to 10 sec
duration. They are valid exercises that present a variability of less than 10%. The highest
value is taken as maximum force.
- Body composition: body compartments estimated greasy, non-fat and body water by
bioelectrical impedance power (Bodystat 1500, Isle of Man, United Kingdom). The BMI is
calculated by dividing weight (Kg) to height (m2) fat-free mass, Fat Free Mass (FFM)
and fat (FM) measured by bioimpedance (). FFM index (FFMi) ratio is calculated by the
FFM (kg) and height (m2). The loss of muscle mass is defined as FFM index <16 kg/m2 for
men and <15 kg/m2 in women.
- Exercise Test:
1. Máximal with cycle ergometer and methodology already known (20), including:
Determining, from the respiratory gases, oxygen consumption, carbon production and
indirect anaerobic threshold, breathing pattern (minute ventilation, tidal volume,
frequency breathing), electrocardiographic monitoring and pulse oximetry during
exercise with heart rate control, blood pressure and dyspnea Borg scale.
2. Submáximal of resistance cycle ergometer at 70% load achieved in the ultimate
test, with time control of resistance primarily, distance walked and control
saturation (pulse oximetry) and heart rate achieved.
3. Test of the 6-minute walk, according to standard guidelines of the ATS.
- Assessment of dyspnea and quality of life:
1. Indices of dyspnea and transition rate measures the functional deterioration, the
magnitude of the task and the magnitude of effort (Test of Mahler).
2. Evaluation quality of life based on the specific questionnaire (CRDQ) proposed by
Guyatt for COPD patients and modified for your understanding in Spanish-speaking
subjects.
- Evaluation of markers of inflammation and catabolism: It will perform a white blood
cell count by flow cytometry and measured the levels of CRP in blood samples by
quantitative real-time PCR. The detection of various cytokines, IL6, IL8, IL10, IL12,
TNF alpha, IGF-1 and MIC-A and MIC-B circulating is carried out by immunosorbent assay
(ELISA) using specific kit for each markers.
- Quadriceps Muscle Biopsy: Biopsies were performed in the middle of the thigh, obtaining
samples of the vastus lateralis of the quadriceps muscle. Samples were obtained in an
outpatient setting. Some of the biopsies were fixed in formalin and included in
paraffin blocks and some will freeze with liquid nitrogen and stored at -80 ° C for
subsequent use in genetic and immunohistochemical study.
For analysis of expression of genes selected, proceed to extract RNA from tissues previously
frozen in liquid nitrogen. This will be used Trizol Reagent (Invitrogen). From isolated RNA
was performed reverse transcription using Superscript II RNase kit reverse transcriptase
(Invitrogen) and the resulting cDNA was used to carry out real-time quantitative PCR. The
PCR reaction was carried out by using fluorochromes such as SYBR Green or Taqman probes
(Applied Biosystems). The following will be evaluated based on their genes into the muscle
transcriptome:
- TNF-alpha and its two receptors (TNFR-I and TNFR-II), the two isoforms muscle IGF-1
(IGF-1EA and FGM) and its specific receptor (IGF-1R).
- Genes linked to the biogenesis: Paired box gene 7 (Pax7), M-cadherin and Myo-D.
- Markers-cellular stress injury: adult isoforms demiosina heavy chain, both embryonic
(MyHC-emb) and perinatal (MyHC-peri).
Immunohistochemical studies were performed in 5 um sections of paraffin tissue blocks
previously. These studies will detect markers such as myosin heavy chains (MyHC) I and II
(for typing and morphometric study fibrillar) N-CAM/CD 56 and Met (for quantification of
satellite cells in muscle tissue) and desmin (for determining the origin muscular). For
detection using the standard technique of immunoperoxidase-biotine.avidins (DakoCytomation,
Dako Denmark) with antibodies specific for each of the markers.
STATISTICAL ANALYSIS:
For comparison of numeric variables between groups used nonparametric or parametric tests,
depending on their distribution (analysis of variance, Student's t test and Mann-Whitney).
To analyze the influence of training on the functional and morphometric variables were also
conducted an analysis of the percentage change [(post value - value pre / pre value) x 100].
To examine the relationship between different variables using the Pearson correlation
coefficients or Spearman, according to the distribution thereof. There will also be a
multivariate analysis, multiple regression. Be considered statistically significant at p
<0.05. The dispersion of a mean value is expressed as mean ± standard deviation.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05825261 -
Exploring Novel Biomarkers for Emphysema Detection
|
||
Completed |
NCT02914340 -
REACH SVS Control Patient Cross-Over Study
|
N/A | |
Completed |
NCT02999685 -
Home-based Health Management of Chronic Obstructive Lung Disease (COPD) Patients
|
N/A | |
Completed |
NCT02238327 -
Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes
|
||
Completed |
NCT02232841 -
Electrical Impedance Imaging of Patients on Mechanical Ventilation
|
N/A | |
Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01710449 -
Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen
|
Phase 1 | |
Completed |
NCT00475007 -
Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema
|
N/A | |
Suspended |
NCT00523094 -
Vibration Response Imaging (VRI) in Patients That Are Candidates for Undergoing Pulmonary Operation Procedure
|
N/A | |
Recruiting |
NCT00129350 -
Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation
|
Phase 1 | |
Completed |
NCT01953523 -
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
|
N/A | |
Completed |
NCT00000621 -
Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)
|
Phase 2 | |
Completed |
NCT00005292 -
Alpha1-antitrypsin Deficiency Registry
|
N/A | |
Recruiting |
NCT04537182 -
Surgical Compared to Bronchoscopic Lung Volume Reduction in Patients With Severe Emphysema
|
N/A | |
Active, not recruiting |
NCT02713347 -
Advancing Symptom Alleviation With Palliative Treatment
|
N/A | |
Recruiting |
NCT04302272 -
STRIVE Post-Market Registry Study
|
||
Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
Completed |
NCT03636347 -
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
|
Phase 2 |